University Hospital Tuebingen
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1388-01-01
- Employees
- -
- Market Cap
- -
Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 14
- Registration Number
- NCT00306111
- Locations
- 🇩🇪
Dept. of Medicine 2, University of Tuebingen, Tuebingen, BW, Germany
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 60
- Registration Number
- NCT00302757
- Locations
- 🇩🇪
Medical Center Charite Benjamin Franklin, Berlin, Germany
🇩🇪University of Dresden Medical Center, Dresden, Germany
🇩🇪South West German Cancer Center, University of Tuebingen Medical Center, Tuebingen, Germany
Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
- Conditions
- Gastrointestinal NeoplasmsNeoplasm Metastasis
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- University Hospital Tuebingen
- Registration Number
- NCT00289445
Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Primary Gastric Diffuse-Large B-Cell Lymphoma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-10-20
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 30
- Registration Number
- NCT00204659
- Locations
- 🇩🇪
University of Giessen, Giessen, Germany
🇩🇪Schwarzwald-Baar Clinic, Villingen-Schwenningen, Germany
🇩🇪Klinikum Reutlingen, Reutlingen, Germany
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
- Conditions
- Hematologic Malignancies
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 61
- Registration Number
- NCT00202917
- Locations
- 🇩🇪
Center for Marrow Transplantation, Essen, Germany
🇩🇪University of Wuerzburg Medical Center, Wuerzburg, Germany
🇩🇪Deutsche Klinik für Diagnostik, Wiesbaden, Germany
Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma
- Conditions
- Carcinoma, Basal Cell
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 100
- Registration Number
- NCT00204555
- Locations
- 🇩🇪
Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen, BW, Germany
Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases
- Conditions
- Melanoma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 51
- Registration Number
- NCT00204581
- Locations
- 🇩🇪
Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen, BW, Germany
Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 1
- Registration Number
- NCT00204594
- Locations
- 🇩🇪
University of Tuebingen, Department of dermatology, Tuebingen, Germany
Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
- Conditions
- Malignant Melanoma
- Interventions
- Biological: mRNA coding for melanoma associated antigens
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 31
- Registration Number
- NCT00204516
- Locations
- 🇩🇪
Department of Dermatology, University of Tuebingen, Tuebingen, Germany
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
- Conditions
- Melanoma
- Interventions
- Drug: pegylated interferon-alpha-2aDrug: interferon-alpha-2a
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 901
- Registration Number
- NCT00204529
- Locations
- 🇩🇪
Arbeitsgemeinschaft Dermatologische Onkologie, Skin Cancer Program, Department of Dermatology, University of Tübingen, Tübingen, BW, Germany